title: [Lymphatic invasion of the bladder wall in T1 superficial bladder carcinoma. Prognostic value].
abstract: BACKGROUND
  It is not usual to use as prognostic factor the bladder lymphatic vessels invasion.
  
  
  METHODS
  519 T1 bladder tumors with complete resection and follow up of one year at least. Prophylaxis with 81 mg of BCG weekly during six weeks in 54%.
  
  
  RESULTS
  Follow up without recurrence of 38 months. 49%. Tumour recurrence of 49% and progression of 7%. 5.8% of the tumours are L1 and 70.7% L0. There are significative statistic relation between lympatic invasion and progression (p. 005), tumoral grade (p. 000) and actual situation (p. 02). 23% of the L1 tumours progressed vs 5% of L0. Prophylaxis with BCG reduces progression risk (33% without treatment vs 16 with BCG (p n.s.)). In multivariate analysis, resected volume (p. 024) and prophylactic treatment are independent variables for recurrence and lymphatic vessels invasion (p. 0478) and tumoral grade (p. 092) for progression.
  
  
  CONCLUSIONS
  1) L1 tumours has more probabilities of progression. 2) BCG disminishes progression rate but this is not statistical significative. 3) We need new markers to select which L1 tumours will progress.
authors.affiliation: Cátedra y Servicio de Urología, Hospital Universitario Virgen Macarena, Fundación Joaquín Albarrán, Sevilla.
authors.forename: J L
authors.initials: JL
authors.lastname: Moyano Calvo
authors.forename: A
authors.initials: A
authors.lastname: Ortiz Gámiz
authors.forename: J M
authors.initials: JM
authors.lastname: Poyato Galán
authors.forename: M
authors.initials: M
authors.lastname: Gutiérrez González
authors.forename: E
authors.initials: E
authors.lastname: Sánchez Sánchez
authors.forename: J L
authors.initials: JL
authors.lastname: Alvarez-Ossorio Fernández
authors.forename: J
authors.initials: J
authors.lastname: Castiñeiras Fernández
mesh_terms: D000283:Administration, Intravesical; D000368:Aged; D001500:BCG Vaccine / Q000627:therapeutic use; D003131:Combined Modality Therapy; D015653:Cystectomy; D018450:Disease Progression; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007167:Immunotherapy; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D009361:Neoplasm Invasiveness; D009364:Neoplasm Recurrence, Local; D009367:Neoplasm Staging; D009378:Neoplasms, Multiple Primary / Q000473:pathology; D011379:Prognosis; D012306:Risk; D001749:Urinary Bladder Neoplasms / Q000473:pathology* / Q000601:surgery / Q000628:therapy
chemical_list: D001500:BCG Vaccine